Abstract
This relation is sometimes described as a double association: venous thromboembolism (VTE) can reveal cancer (so-called Trousseau syndrome), but cancer and its treatment are also risk factors for VTE. Lung cancer, frequent and serious, is one of the greatest purveyors of VTE, a disease that pneumologists and oncologists must often confront in diagnosis, prevention, and treatment. This article investigates the epidemiological, prevention, and treatment aspects of VTE in cancer patients, particularly those with lung cancer, but also discusses diagnostic specificities and, briefly, the possible antitumor effect of heparins.
MeSH terms
-
Anticoagulants / adverse effects
-
Anticoagulants / therapeutic use
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Carcinoma, Bronchogenic / mortality
-
Carcinoma, Bronchogenic / physiopathology*
-
Heparin / adverse effects
-
Heparin / therapeutic use
-
Humans
-
Lung Neoplasms / mortality
-
Lung Neoplasms / physiopathology*
-
Palliative Care / methods*
-
Survival Rate
-
Thrombosis / drug therapy
-
Thrombosis / etiology*
-
Thrombosis / mortality
-
Venous Thromboembolism / drug therapy
-
Venous Thromboembolism / etiology*
-
Venous Thromboembolism / mortality
Substances
-
Anticoagulants
-
Antineoplastic Agents
-
Heparin